Capecitabine - A novel oral tumor-activated fluoropyrimidine

Onkologie

Volumn 21, Issue 6, 1998, Pages 451-458

  Frings, S ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Capecitabine; Fluoropyrimidine; Phase I II studies; Thymidine phosphorylase

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TEGAFUR; THYMIDINE PHOSPHORYLASE; URACIL;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SPECIFICITY; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; STOMACH CANCER;

EID: 0032414730     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026887     Document Type: Review

References (30)

1. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J: Fluorinated pyrimidines; a new class of tumour-inhibitory compounds. Nature 1957; 179:663-666.
2. Peters GFJ, Groeningen van CJ: Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 1991;2:469-480.
3. Hilgenfeld RU, Kreuser ED: Immunological and biochemical modulation in the treatment of advanced colorectal cancer: Update and future directions. Curr Top Microbiol Immunol 1996;213 (Pt3):217-240.
4. By the Advanced Colorectal Cancer Meta-Analysis Project: Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW, Valone F, Labianca R, Doroshow JH, Petrelli N: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer. Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
5. By the Meta-analysis Group in Cancer: Piedbois P: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16: 301-308.
6. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-432.
7. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, MacDonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-507.
8. Rougier P, Buyse M, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Benedetti J, Leichman C, Macdonald J, Laplanche A, Pignon JP, Lokich J, Fryer J, Isacson R, Brufman G, Piedbois P: Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997;16:267a(Abstr 946).
9. Lokich J: Protracted infusional 5-fluorouracil for colorectal cancer. Tumori 1997;83 (suppl 1):53-55.
10. Ishitsuka H, Miwa M, Ishikawa T, Ura M, Sawada N, Nishida M, Fukase Y, Yamamoto T, Mori K, Arasaki M, et al: Capecitabine: An orally available fluoropyrimidine with tumor selective activity. Annu Meet Am Assoc Cancer Proc Res 1995;36:A2426.
11. Folkman J: What is the role of thymidine phosphorylase in tumor angiogenesis? J Natl Cancer Inst 1996;88:1091-1092.
12. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338:557-562.
13. Moghaddam A, Zhang HT, Fan TPD, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995;92:998-1002.
14. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T: Expression of platelet-derived endothelial cell growth factor / thymidine phosphorylase in human breast cancer. Int J Cancer 1995;64:79-82.
15. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ: The influence of oxygen tension and pH on the expression of platelet derived endothelial cell growth factor / thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997;57:570-572.
16. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237.
17. Pinedo HM, Peters GFJ: Ruorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
18. Ishikawa T, Sawada N, Sekiguchi F, Fukase Y, Ishitsuka H: Xeloda™ (capecitabine), a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Annu Meet Am Soc Clin Oncol 1997;16:A796.
19. Ishikawa T, Utoh M, Sawada N, Sekiguchi F, Ishitsuka H: Xeloda™ (capecitabine): An orally available tumor-selective fluoropyrimidine carbamate. Proc Annu Meet Am Soc Clin Oncol 1997; 16:A727.
20. Kawashima A, Kobayashi K, Abo T, Imamura I, Horii I: Toxicological assessment of a novel anti-tumor agent capecitabine (Ro 09-1978, 5′-DFCR derivative) - Species differences and improvement of intestinal toxicity. J Toxicol Sci 1995;20:514 (Abstr C16).
21. Meropol NG, Budman DR, Creaven PJ, Lichtman S, Berghorn E, Behr J, Gordon RJ, Osterwalder B: A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann Oncol 1996;7 (suppl 1):A298.
22. Hughes M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Kaye S, Verweij J: A phase I study of intermittent daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer. Ann Oncol 1996;7(suppl 1):A297.
23. Taguchi T, Ishitani T, Saitoh K, Kurihara M, Tominaga T, Fukuyama Y, Saigenji K, Toge T, Takashima S, Sugimachi K, Hara Y: A Japanese phase I study of continous twice daily treatment with capecitabine in patients with advanced and/or metastatic solid tumors. Ann Oncol 1996;7(suppl 1):A299.
24. Dirix LY, Bissett D, Oosterom van AT, Allman DS, Osterwalder B, Cassidy J: A phase I study of capecitabine in combination with oral leucovorin in patients with advanced and/or metastatic tumours. Ann Oncol 1996;7(suppl 5):A598O.
25. Villalona-Calero M, Moczygemba J, Atkins I, Thurman A, Rodriguez G, McCune C, Drengler R, Griffin T, Osterwalder B, Hoff von D: Paclitaxel-capecitabine: Results of a dual escalation phase I and pharmacokinetic (PK) study. Ann Oncol 1996;7 (suppl 5):A611P
26. Vasey PA, Pronk L, Twelves C, Sparreboom A, Wilson P, Gordon RJ, Osterwalder B, Verweij J: Phase I and pharmacokinetic study of Xeloda™ (capecitabine) in combination with docetaxel. Eur J Cancer 1997;33(suppl 8):A1.113.
27. Twelves C, Budman DR, Creaven PJ, Schellens JH, Kuruma I, Dumont E, Osterwalder B, Reigner BG: Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Annu Meet Am Soc Clin Oncol 1996;15:A1509.
28. Schneller J, Cassidy J, Reigner B, Roos B, Pietrzak C, Springer B, Ishitsuka H, Dumont E: Tumor selective activation of capecitabine in colorectal cancer patients. Onkologie 1997;20(suppl 1):A732.
29. Findlay M, Cutsem van E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Pazdur R, Verweij J: A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc Annu Meet Am Soc Clin Oncol 1997;16:A798.
30. Blum JL, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Burger HU, Brown C, Griffin T: A multicenter phase II trial of Xeloda™ (capecitabine) in paclitaxel-refractory metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol 1998;17:A476.